ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDXC
CUSIPN/A
Phone949-419-0288
Debt
Debt-to-Equity Ratio0.01
Current Ratio4.24
Quick Ratio3.65
Price-To-Earnings
Trailing P/E Ratio-13.17
Forward P/E Ratio-9.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.20 million
Price / Sales11.97
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book4.61
Profitability
EPS (Most Recent Fiscal Year)($0.35)
Net Income$-11,370,000.00
Net Margins-82.82%
Return on Equity-65.33%
Return on Assets-53.31%
Miscellaneous
Employees74
Outstanding Shares55,060,000
Market Cap$248.85 million
Chromadex (NASDAQ:CDXC) Frequently Asked Questions
What is Chromadex's stock symbol?
Chromadex trades on the NASDAQ under the ticker symbol "CDXC."
How were Chromadex's earnings last quarter?
Chromadex Corp (NASDAQ:CDXC) issued its earnings results on Thursday, August, 9th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.02. The company had revenue of $7.80 million for the quarter, compared to analyst estimates of $7.50 million. Chromadex had a negative return on equity of 65.33% and a negative net margin of 82.82%. View Chromadex's Earnings History.
When is Chromadex's next earnings date?
What price target have analysts set for CDXC?
2 equities research analysts have issued 12 month target prices for Chromadex's stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Chromadex's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price. View Analyst Price Targets for Chromadex.
What is the consensus analysts' recommendation for Chromadex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.
What are Wall Street analysts saying about Chromadex stock?
Here are some recent quotes from research analysts about Chromadex stock:
- 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (8/15/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 21.4x EV-to-EBITDA multiple to 2020 EBITDA per share of $0.50, discounted back at 12%, which yields $8.00 per share. Risks include: (1) slower- than-projected sales growth; (2) unfavorable clinical data; (3) failure to secure regulatory approval; and (4) inability to achieve market traction." (8/7/2018)
Who are some of Chromadex's key competitors?
Some companies that are related to Chromadex include Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), True Drinks Holdings, Inc Common Stock (TRUU), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ).
Who are Chromadex's key executives?
Chromadex's management team includes the folowing people:
- Mr. Frank Louis Jaksch Jr., Co-Founder, CEO & Director (Age 50)
- Mr. Robert N. Fried, Pres, COO & Director (Age 58)
- Mr. Kevin M. Farr, Chief Financial Officer (Age 60)
- Mr. Troy Allen Rhonemus, Exec. VP (Age 45)
- Andrew Johnson, Director of Investor Relations
Has Chromadex been receiving favorable news coverage?
News headlines about CDXC stock have been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chromadex earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 47.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Chromadex.
Who are Chromadex's major shareholders?
Chromadex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.43%), Tieton Capital Management LLC (1.66%), First Republic Investment Management Inc. (0.49%), Bank of New York Mellon Corp (0.18%), North Star Investment Management Corp. (0.13%) and Schwab Charles Investment Management Inc. (0.13%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Institutional Ownership Trends for Chromadex.
Which major investors are selling Chromadex stock?
Which major investors are buying Chromadex stock?
CDXC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Tieton Capital Management LLC, First Republic Investment Management Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., GSA Capital Partners LLP and Rhumbline Advisers. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Insider Buying and Selling for Chromadex.
How do I buy shares of Chromadex?
Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chromadex's stock price today?
One share of CDXC stock can currently be purchased for approximately $4.61.
How big of a company is Chromadex?
Chromadex has a market capitalization of $248.85 million and generates $21.20 million in revenue each year. The company earns $-11,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Chromadex employs 74 workers across the globe.
How can I contact Chromadex?
Chromadex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]
MarketBeat Community Rating for Chromadex (NASDAQ CDXC)
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
